Evidence map›Paper›PMID 42493668›Full record

ArticlePituitary2026

GH Stimulation testing is unnecessary in patients with hypothalamic-pituitary disease, preserved pituitary function, and IGF-I SDS ≥ 0.

Valentina Gasco, Daniela Cuboni, Michela Sibilla, Francesca Mocellini, Alice Martinotti, Davide Lucisano, Ezio Ghigo, Gianluca Aimaretti, Silvia Grottoli, Mauro Maccario

Abstract read
In one paragraph

Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valentina GascoDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy. valentina.gasco@unito.it.ORCID http://orcid.org/0000-0002-6491-5731
Daniela CuboniDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Michela SibillaDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Francesca MocelliniDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Alice MartinottiDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Davide LucisanoDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Ezio GhigoDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Gianluca AimarettiDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Silvia GrottoliDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Mauro MaccarioDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn adults with hypothalamic-pituitary disease, the presence of at least three additional pituitary hormone deficiencies, with or without markedly reduced IGF-I levels, is considered diagnostic of growth hormone deficiency (GHD) without the need for stimulation testing. In all other cases, dynamic testing is required despite its well-recognized limitations. To date, no formal strategy has been proposed to exclude GHD without performing stimulation tests. This study aims to develop a probabilistic model to estimate the likelihood of GHD in adults with hypothalamic-pituitary disease but no additional pituitary hormone deficiencies, based on IGF-I standard deviation scores (SDS).

methodsWe combined literature-derived data on: (1) the probability of an impaired GH response to stimulation tests in patients with hypothalamic-pituitary disease and preserved anterior pituitary function; and (2) the probability that adults with isolated GHD present IGF-I SDS values ≥ 0, ≥ 0.5, or ≥ 1. A Bayesian approach was applied to estimate the post-test probability of GHD in patients meeting these criteria.

resultAcross all models, the estimated probability of adult-onset GHD ranged from 6.5% to 19.8%, while the probability of childhood-onset GHD ranged from 2.9% to 9.1%, consistently remaining below 20%, regardless of the IGF-I SDS cut-off applied.

conclusionIn adults with hypothalamic-pituitary disease but no additional hormonal deficiencies, IGF-I SDS values ≥ 0 identify a subgroup with a low, clinically acceptable probability of GHD, in whom stimulation testing may reasonably be avoided. This proof-of-concept model supports a simplified, probability-based diagnostic approach.

Indexed as

Human Growth HormoneHypothalamic DiseasesInsulin-Like Growth Factor IPituitary DiseasesPituitary GlandAdultBayes TheoremFemaleHumansHuman Growth HormoneInsulin-Like Growth Factor IAdult growth hormone deficiencyBayesian analysisDiagnostic probabilityGH stimulation testingIGF-IPituitary function

Identifiers

PMID42493668
PMCPMC13395983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.